IL138604A0 - Inflammatory mediator antagonists - Google Patents
Inflammatory mediator antagonistsInfo
- Publication number
- IL138604A0 IL138604A0 IL13860499A IL13860499A IL138604A0 IL 138604 A0 IL138604 A0 IL 138604A0 IL 13860499 A IL13860499 A IL 13860499A IL 13860499 A IL13860499 A IL 13860499A IL 138604 A0 IL138604 A0 IL 138604A0
- Authority
- IL
- Israel
- Prior art keywords
- antagonists
- inflammatory mediator
- mediator antagonists
- osm
- inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806530.3A GB9806530D0 (en) | 1998-03-26 | 1998-03-26 | Inflammatory mediator |
PCT/GB1999/000943 WO1999048523A2 (en) | 1998-03-26 | 1999-03-25 | Antagonists of the inflammatory mediator oncostatin m (osm) |
Publications (1)
Publication Number | Publication Date |
---|---|
IL138604A0 true IL138604A0 (en) | 2001-10-31 |
Family
ID=10829337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13860499A IL138604A0 (en) | 1998-03-26 | 1999-03-25 | Inflammatory mediator antagonists |
Country Status (20)
Country | Link |
---|---|
US (5) | US6706266B1 (ja) |
EP (2) | EP1849478A3 (ja) |
JP (2) | JP3825255B2 (ja) |
KR (1) | KR20010034672A (ja) |
CN (1) | CN1295482A (ja) |
AT (1) | ATE338565T1 (ja) |
AU (1) | AU3046399A (ja) |
BR (1) | BR9909077A (ja) |
CA (1) | CA2325585A1 (ja) |
CY (1) | CY1105722T1 (ja) |
DE (1) | DE69933115T2 (ja) |
DK (1) | DK1071449T3 (ja) |
ES (1) | ES2272058T3 (ja) |
GB (1) | GB9806530D0 (ja) |
HU (1) | HUP0101690A2 (ja) |
IL (1) | IL138604A0 (ja) |
PL (1) | PL343431A1 (ja) |
PT (1) | PT1071449E (ja) |
WO (1) | WO1999048523A2 (ja) |
ZA (1) | ZA200005076B (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
WO2004043361A2 (en) * | 2002-11-08 | 2004-05-27 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
AU4878601A (en) * | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
WO2003035048A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Ag | Methods for the treatment of osteoarthritis and compositions thereof |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
JP4803789B2 (ja) * | 2004-02-03 | 2011-10-26 | 独立行政法人科学技術振興機構 | 疼痛を処置するための薬学的組成物 |
SI1730191T1 (sl) | 2004-03-30 | 2011-11-30 | Glaxo Group Ltd | Imunoglobulin-vezavni hOSM |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US20070207187A1 (en) * | 2004-09-29 | 2007-09-06 | Mizuo Yajima | Functional Composition Or Food Comprising Whey Protein, Antibody Derived From Milk Or Antibody |
US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
EP1671642A1 (en) * | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
WO2006074192A2 (en) * | 2005-01-03 | 2006-07-13 | Bionaut Pharmaceuticals, Inc. | Treatment of inflammatory disorders |
EP1877556B1 (en) * | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain |
CA2645934C (en) * | 2005-08-02 | 2014-04-29 | Trustees Of Tufts College | Methods for stepwise deposition of silk fibroin coatings |
WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
US8030290B2 (en) * | 2007-12-07 | 2011-10-04 | City Of Hope | Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
US8309688B2 (en) | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
CA2753332A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2011080050A2 (en) | 2009-12-11 | 2011-07-07 | Novartis Ag | Binding molecules |
SG182590A1 (en) | 2010-01-28 | 2012-08-30 | Glaxo Group Ltd | Cd127 binding proteins |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
DK2580240T3 (en) | 2010-06-14 | 2019-03-25 | Lykera Biomed S A | S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF |
KR101920250B1 (ko) * | 2010-10-13 | 2018-11-20 | 얀센 바이오테크 인코포레이티드 | 인간 온코스타틴 m 항체 및 이용 방법 |
MX2013005024A (es) | 2010-11-08 | 2013-11-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-il-6 receptor administrado subcutaneamente. |
KR101947356B1 (ko) * | 2010-11-23 | 2019-02-12 | 글락소 그룹 리미티드 | 온코스타틴 m (osm)에 대한 항원 결합 단백질 |
US9475876B2 (en) | 2012-05-11 | 2016-10-25 | Wakayama Medical University | Anti oncostatin M receptor beta antibody used for treating atopic dermatitis |
NZ713636A (en) | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
US10307487B2 (en) * | 2013-07-09 | 2019-06-04 | President And Fellows Of Harvard College | Microvessel endothelial cell surface markers and uses thereof |
US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
EP3069137A1 (en) | 2013-11-05 | 2016-09-21 | Novartis Ag | Organic compounds |
JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
CN104096219A (zh) * | 2014-07-08 | 2014-10-15 | 武汉大学 | Ⅱ型抑瘤素m受体(osmr)在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
US20170327573A1 (en) * | 2014-09-24 | 2017-11-16 | Universitá Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
KR20170132143A (ko) | 2015-01-29 | 2017-12-01 | 옥스포드 유니버시티 이노베이션 리미티드 | 바이오마커 |
GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US646727A (en) * | 1899-06-20 | 1900-04-03 | Columbia Motor And Mfg Company | Steam-generator. |
US5681930A (en) * | 1985-12-20 | 1997-10-28 | Bristol-Myers Squibb Company | Anti-oncostatin M monoclonal antibodies |
US5618715A (en) * | 1985-12-20 | 1997-04-08 | Oncogen Limited Partnership | Oncostatin M and novel compositions having anti-neoplastic activity |
JPS6463395A (en) | 1987-05-04 | 1989-03-09 | Oncogen | Oncostatin m and novel composition having antitumor activity |
JPH04502769A (ja) | 1989-04-10 | 1992-05-21 | オンコーゲン リミテッド パートナーシップ | オンコスタチンmを使用したヒト内皮細胞増殖およびエフェクター機能の制御法 |
US5814307A (en) | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
CA2070171A1 (en) | 1989-12-08 | 1991-06-09 | Peter S. Linsley | Proteins with oncostatin m activity and process for their preparation |
IL97623A (en) * | 1990-03-29 | 1996-01-19 | Bristol Myers Squibb Co | Monoclonal antibodies against oncostatin M, their preparation and pharmaceutical preparations containing them |
DE4011684A1 (de) | 1990-04-06 | 1991-10-10 | Schering Ag | Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung |
CA2055122A1 (en) | 1990-11-13 | 1992-05-14 | Robert I. Grove | Methods for stimulating ldl uptake and ldl receptor expression |
AU666866B2 (en) | 1991-08-30 | 1996-02-29 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US6171824B1 (en) | 1991-08-30 | 2001-01-09 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US5262522A (en) * | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05304986A (ja) | 1992-04-28 | 1993-11-19 | Tosoh Corp | gp130蛋白質に対するモノクロ−ナル抗体 |
US5744442A (en) | 1992-08-26 | 1998-04-28 | Bristol Meyers Squibb Company | Regulation of cellular invasiveness |
US5460810A (en) | 1992-09-02 | 1995-10-24 | Genetics Institute, Inc. | Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11 |
IT1261787B (it) | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
FR2707882B1 (fr) * | 1993-07-23 | 1997-08-01 | Immunotech Sa | Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant. |
US5451411A (en) * | 1993-10-15 | 1995-09-19 | University Of Washington | Methods and compositions for the oral delivery of therapeutic agents |
US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
GB9419021D0 (en) | 1994-09-21 | 1994-11-09 | Applied Research Systems | Therapeutic protein |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
CA2178256A1 (en) | 1995-06-06 | 1996-12-07 | Christopher H. Clegg | Oncostatin m induced hematopoiesis |
WO1997016202A1 (en) | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
WO1998018483A1 (en) | 1996-10-25 | 1998-05-07 | Bristol-Myers Squibb Company | Oncostatin m for treating inflammation |
US5958442A (en) * | 1997-10-24 | 1999-09-28 | Bristol-Myers Squibb Company | Oncostatin M for treating inflammation |
GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
-
1998
- 1998-03-26 GB GBGB9806530.3A patent/GB9806530D0/en not_active Ceased
-
1999
- 1999-03-25 CA CA002325585A patent/CA2325585A1/en not_active Abandoned
- 1999-03-25 IL IL13860499A patent/IL138604A0/xx unknown
- 1999-03-25 CN CN99804497A patent/CN1295482A/zh active Pending
- 1999-03-25 AT AT99911954T patent/ATE338565T1/de active
- 1999-03-25 WO PCT/GB1999/000943 patent/WO1999048523A2/en active IP Right Grant
- 1999-03-25 ES ES99911954T patent/ES2272058T3/es not_active Expired - Lifetime
- 1999-03-25 BR BR9909077-5A patent/BR9909077A/pt not_active Application Discontinuation
- 1999-03-25 EP EP06119544.2A patent/EP1849478A3/en not_active Withdrawn
- 1999-03-25 PL PL99343431A patent/PL343431A1/xx not_active Application Discontinuation
- 1999-03-25 PT PT99911954T patent/PT1071449E/pt unknown
- 1999-03-25 EP EP99911954A patent/EP1071449B1/en not_active Expired - Lifetime
- 1999-03-25 AU AU30463/99A patent/AU3046399A/en not_active Abandoned
- 1999-03-25 HU HU0101690A patent/HUP0101690A2/hu unknown
- 1999-03-25 DK DK99911954T patent/DK1071449T3/da active
- 1999-03-25 US US09/276,147 patent/US6706266B1/en not_active Expired - Lifetime
- 1999-03-25 KR KR1020007010639A patent/KR20010034672A/ko not_active Application Discontinuation
- 1999-03-25 DE DE69933115T patent/DE69933115T2/de not_active Expired - Lifetime
- 1999-03-25 JP JP2000537570A patent/JP3825255B2/ja not_active Expired - Lifetime
-
2000
- 2000-09-21 ZA ZA200005076A patent/ZA200005076B/en unknown
-
2003
- 2003-05-21 US US10/442,289 patent/US20040081650A1/en not_active Abandoned
-
2005
- 2005-10-27 US US11/260,844 patent/US7291332B2/en not_active Expired - Fee Related
-
2006
- 2006-05-08 JP JP2006129454A patent/JP2006290893A/ja not_active Withdrawn
- 2006-10-24 CY CY20061101520T patent/CY1105722T1/el unknown
-
2007
- 2007-05-09 US US11/746,090 patent/US8003101B2/en not_active Expired - Fee Related
- 2007-09-20 US US11/858,308 patent/US20080019967A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69933115D1 (de) | 2006-10-19 |
US7291332B2 (en) | 2007-11-06 |
US6706266B1 (en) | 2004-03-16 |
KR20010034672A (ko) | 2001-04-25 |
JP2006290893A (ja) | 2006-10-26 |
CN1295482A (zh) | 2001-05-16 |
PL343431A1 (en) | 2001-08-13 |
DK1071449T3 (da) | 2007-01-02 |
WO1999048523A2 (en) | 1999-09-30 |
AU3046399A (en) | 1999-10-18 |
JP3825255B2 (ja) | 2006-09-27 |
WO1999048523A3 (en) | 1999-11-25 |
ZA200005076B (en) | 2001-09-21 |
CY1105722T1 (el) | 2010-12-22 |
CA2325585A1 (en) | 1999-09-30 |
HUP0101690A2 (hu) | 2001-08-28 |
US20060093602A1 (en) | 2006-05-04 |
EP1849478A2 (en) | 2007-10-31 |
US20080044409A1 (en) | 2008-02-21 |
US20040081650A1 (en) | 2004-04-29 |
US20080019967A1 (en) | 2008-01-24 |
EP1849478A3 (en) | 2013-05-29 |
BR9909077A (pt) | 2000-12-05 |
EP1071449A2 (en) | 2001-01-31 |
DE69933115T2 (de) | 2007-04-05 |
ES2272058T3 (es) | 2007-04-16 |
EP1071449B1 (en) | 2006-09-06 |
ATE338565T1 (de) | 2006-09-15 |
JP2002507580A (ja) | 2002-03-12 |
GB9806530D0 (en) | 1998-05-27 |
US8003101B2 (en) | 2011-08-23 |
PT1071449E (pt) | 2006-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL138604A0 (en) | Inflammatory mediator antagonists | |
CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
EA200301073A1 (ru) | N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора | |
MY113806A (en) | Antiparasitic marcfortines and paraherquamides | |
NO983431L (no) | Anti-klöemidler | |
EA200300580A1 (ru) | Соединения лактама | |
PT1671949E (pt) | Piridinilaminas substituídas | |
HK1046004B (zh) | 重組脫氧核糖核酸的明膠 | |
HK1029595A1 (en) | Cyclic antagonists of c5a receptors and g protein-coupled receptors | |
EA200400510A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
IS5769A (is) | Taugasæknir thættir | |
NO970162D0 (no) | Substituerte pyrimidinforbindelser og anvendelse derav | |
TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
DK0842934T3 (da) | 5-HT1F agonister | |
TR200001012T2 (tr) | Yeni ariloksi-alkil-dialkilaminler. | |
EA200400582A1 (ru) | Тиофен- и тиазолсульфонамиды в качестве противоопухолевых средств | |
WO2003048301A3 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
BR0207933A (pt) | Mutantes de interleucina-18, sua produção e uso | |
ID26034A (id) | Helai serat kaca yang dilapisi dengan pelumas anorganik | |
IT1293778B1 (it) | 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli | |
EA200100516A1 (ru) | Производные 3,3-биарилпиперидина и 2,2-биарилморфолина | |
MY141607A (en) | Lactam compound | |
ATE232081T1 (de) | Orale zusammensetzung enthaltend perlit | |
ATE441642T1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren |